^
5d
Diagnostic challenges in pediatric lymphomas (PubMed, Pathologie (Heidelb))
Their diagnosis requires careful consideration to accurately distinguish rare indolent entities, recently defined large B‑cell lymphomas, and reactive mimics. Recent classifications, including the newly introduced WHO Classification of Pediatric Tumors, increasingly reflect these unique aspects.
Review • Journal
|
ALK (Anaplastic lymphoma kinase) • IRF4 (Interferon regulatory factor 4)
|
ALK positive
5d
Trial completion date
|
Valcyte (valganciclovir)
7d
An improved algorithm for genetic diagnostics of aggressive B-cell lymphomas in pediatric oncohematology: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology (PubMed, Arkh Patol)
An improved diagnostic algorithm based on the combined use of FISH and NGS methods makes it possible to increase the accuracy of identification of genetic subtypes of aggressive B-cell lymphomas in children. This helps to categorize the diagnosis based on the molecular and genetic characteristics of the tumor, paving the way for improved prognosis and treatment effectiveness.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
TP53 mutation • TP53 deletion
13d
Case Report: A case of cervical burkitt lymphoma and literature review. (PubMed, Front Oncol)
Immunohistochemical analysis revealed positivity for B-cell markers (CD20, CD79α, etc.), with MYC expression in approximately 80% of cells, fluorescence in situ hybridization staining showed positivity for MYC translocation and molecular testing confirmed IG rearrangement. The diagnosis of Burkitt's lymphoma is based on its distinctive histological morphology in combination with immunohistochemistry and molecular testing.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
14d
Diagnostic challenges in Burkitt's lymphoma with skull base and paravertebral involvement, and hearing loss: a case report. (PubMed, J Med Case Rep)
This case underscores the importance of recognizing atypical presentations of Burkitt's lymphoma, such as skull base involvement and hearing loss. A high index of suspicion and a multimodal diagnostic approach (imaging and histopathology) were crucial for accurate diagnosis. Early identification of such rare presentations is vital to initiate prompt, appropriate therapy and improve patient outcomes.
Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
19d
Germline Homozygous RAG1 Missense Variant Associated With Epstein-Barr Virus Negative Childhood Burkitt Lymphoma: A Case Report. (PubMed, J Pediatr Hematol Oncol)
The patient responded to chemotherapy and remains in remission under follow-up. In conclusion, this case expands the phenotypic spectrum of hypomorphic RAG1 variants to include EBV-negative Burkitt lymphoma without overt immunodeficiency, suggesting a possible link between partial RAG1 dysfunction and pediatric lymphoma susceptibility.
Journal
|
RAG1 (Recombination Activating 1)
1m
Cardiac mass in a patient with HIV infection: A case report and literature review. (PubMed, Exp Ther Med)
The treatment was well tolerated, with a notable reduction in the cardiac mass and no cardiovascular complications associated with treatment during monitoring of the patient. A literature review was conducted to identify all the documented cases of adult cardiac BL of the past 15 years, outlining the low prevalence and high risk of these lymphoid tumors and main diagnostic methods, highlighting the importance of early imaging and multidisciplinary management of these rare but life-threatening cases.
Journal
|
CD4 (CD4 Molecule)
1m
Higher chemical complementarity of EBV epitopes and IGH CDR3s correlates with better outcomes for lymphoma and ovarian cancer. (PubMed, Cancer Causes Control)
This latter result may be relevant to the occasional misdiagnosis of lymphoma for ovarian epithelial carcinoma. In sum, the results justify a more detailed study of the role of EBV and the anti-EBV immune response in the ovarian cancer and lymphoma settings.
Journal
|
IGH (Immunoglobulin Heavy Locus)
1m
Malignancy Ratio in Pediatric Patients with Hereditary Multiple Exostoses: True Association or Reporting Bias? (PubMed, Pediatr Rep)
Although a definitive causal relationship cannot be established, hematologic malignancies in pediatric HME patients appear to be disproportionately represented among reported cases. This finding highlights the need for further investigation through large-scale, population-based studies incorporating both clinical and genetic data.
Journal
|
EXT1 (Exostosin Glycosyltransferase 1)
1m
NCI-2011-01123: Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1/2, N=276, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine
2ms
Enrollment open
|
BCL2 (B-cell CLL/lymphoma 2)
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
2ms
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene (clinicaltrials.gov)
P1/2, N=50, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Dec 2025 --> Mar 2026
Trial initiation date
|
BCL2 (B-cell CLL/lymphoma 2)
|
pidnarulex (CX-5461)